BUZZ-Oncolytics Biotech Inc: Lead cancer drug gets orphan drug status

Wed Apr 29, 2015 7:41am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Drug developer's U.S.-listed shares up 6.21 pct at $0.75 premarket

** Company's lead pancreatic cancer drug, Reolysin, gets orphan drug status from European health regulator

** Orphan status, granted to drugs developed to treat rare diseases, gives developer several incentives including seven-year U.S. marketing exclusivity

** Up to Tuesday's close, stock gained 32 pct this year